New pill could control debilitating muscle and skin disease

NCT ID NCT05437263

Ongoing Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an oral medication called brepocitinib can help adults with dermatomyositis, an autoimmune disease that causes muscle weakness and skin rashes. About 241 participants will receive either the active drug or a placebo pill for 52 weeks to see which group shows more improvement in their symptoms. The main goal is to see if the drug reduces disease activity in both muscles and skin better than the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Trial Site

Phoenix, Arizona, 85028, United States
Clinical Trial Site

Scottsdale, Arizona, 85258, United States
Clinical Trial Site

Scottsdale, Arizona, 85259, United States
Clinical Trial Site

Irvine, California, 92617, United States
Clinical Trial Site

Los Angeles, California, 90095, United States
Clinical Trial Site

San Francisco, California, 94115, United States
Clinical Trial Site

Aurora, Colorado, 80045, United States
Clinical Trial Site

Denver, Colorado, 80230, United States
Clinical Trial Site

Boynton Beach, Florida, 33472, United States
Clinical Trial Site

Gainesville, Florida, 32606, United States
Clinical Trial Site

Jacksonville, Florida, 32224, United States
Clinical Trial Site

Plantation, Florida, 33324, United States
Clinical Trial Site

Tampa, Florida, 33613, United States
Clinical Trial Site

Atlanta, Georgia, 30322, United States
Clinical Trial Site

Augusta, Georgia, 30912, United States
Clinical Trial Site

Marietta, Georgia, 30060, United States
Clinical Trial Site

Chicago, Illinois, 60637, United States
Clinical Trial Site

Iowa City, Iowa, 52242, United States
Clinical Trial Site

Kansas City, Kansas, 66160, United States
Clinical Trial Site

New Orleans, Louisiana, 70112, United States
Clinical Trial Site

New Orleans, Louisiana, 70433, United States
Clinical Trial Site

Baltimore, Maryland, 21224, United States
Clinical Trial Site

Boston, Massachusetts, 02115, United States
Clinical Trial Site

Ann Arbor, Michigan, 48103, United States
Clinical Trial Site

Minneapolis, Minnesota, 55455, United States
Clinical Trial Site

Rochester, Minnesota, 55905, United States
Clinical Trial Site

Manhasset, New York, 11030, United States
Clinical Trial Site

New York, New York, 10017, United States
Clinical Trial Site

New York, New York, 10021, United States
Clinical Trial Site

Cincinnati, Ohio, 45267, United States
Clinical Trial Site

Cleveland, Ohio, 44195, United States
Clinical Trial Site

Oklahoma City, Oklahoma, 73116, United States
Clinical Trial Site

Portland, Oregon, 97239, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19104, United States
Clinical Trial Site

Pittsburgh, Pennsylvania, 15213, United States
Clinical Trial Site

Jackson, Tennessee, 38305, United States
Clinical Trial Site

Austin, Texas, 78756, United States
Clinical Trial Site

Houston, Texas, 77030, United States
Clinical Trial Site

Irving, Texas, 75039, United States
Clinical Trial Site

Quilmes, Buenos Aires, B1878DVB, Argentina
Clinical Trial Site

Caba, Buenos Aires F.D., 1425, Argentina
Clinical Trial Site

Mendoza, 5519, Argentina
Clinical Trial Site

Leuven, 3000, Belgium
Clinical Trial Site

Plovdiv, 4000, Bulgaria
Clinical Trial Site

Plovdiv, 4001, Bulgaria
Clinical Trial Site

Plovdiv, 4004, Bulgaria
Clinical Trial Site

Sofia, 1407, Bulgaria
Clinical Trial Site

Vancouver, British Colombia, V5Y1K2, Canada
Clinical Trial Site

Newmarket, Ontario, L3Y 5G8, Canada
Clinical Trial Site

Concepción, Región del Biobío, 4070280, Chile
Clinical Trial Site

Recoleta, 8420383, Chile
Clinical Trial Site

Santiago, 7640881, Chile
Clinical Trial Site

Santiago, 8331150, Chile
Clinical Trial Site

Temuco, 4800827, Chile
Clinical Trial Site

Prague, 128 00, Czechia
Clinical Trial Site

Mainz, Rhineland-Palatinate, 55131, Germany
Clinical Trial Site

Berlin, 10117, Germany
Clinical Trial Site

Berlin, 15562, Germany
Clinical Trial Site

Dresden, 01307, Germany
Clinical Trial Site

Essen, 45147, Germany
Clinical Trial Site

Freiburg im Breisgau, 79106, Germany
Clinical Trial Site

Debrecen, 4032, Hungary
Clinical Trial Site

Pécs, 7632, Hungary
Clinical Trial Site

Szeged, 6720, Hungary
Clinical Trial Site

Ashkelon, 7830604, Israel
Clinical Trial Site

Haifa, 3109601, Israel
Clinical Trial Site

Poria – Neve Oved, 1528001, Israel
Clinical Trial Site

Tel Aviv, 6423906, Israel
Clinical Trial Site

Tel Litwinsky, 52621, Israel
Clinical Trial Site

Bari, 70126, Italy
Clinical Trial Site

Pavia, 27100, Italy
Clinical Trial Site

Roma, 00168, Italy
Clinical Trial Site

Torino, 10126, Italy
Clinical Trial Site

Monterrey, Nuevo León, 64718, Mexico
Clinical Trial Site

Mérida, Yucatán, 97070, Mexico
Clinical Trial Site

Guadalajara, 44690, Mexico
Clinical Trial Site

Mexico City, 06700, Mexico
Clinical Trial Site

San Luis Potosí City, 78290, Mexico
Clinical Trial Site

Nijmegen, Gelderland, 6500 HB, Netherlands
Clinical Trial Site

Amsterdam, 1105 AZ, Netherlands
Clinical Trial Site

Bialystok, Podlaskie Voivodeship, 15-704, Poland
Clinical Trial Site

Krakow, 30-363, Poland
Clinical Trial Site

Lublin, 20-400, Poland
Clinical Trial Site

Lublin, 20-607, Poland
Clinical Trial Site

Nowa Sól, 67-100, Poland
Clinical Trial Site

Poznan, 61-293, Poland
Clinical Trial Site

Warsaw, 02-637, Poland
Clinical Trial Site

Vila Nova de Gaia, Porto District, 4434-502, Portugal
Clinical Trial Site

Guimarães, 4835-044, Portugal
Clinical Trial Site

Lisbon, 1649-028, Portugal
Clinical Trial Site

Porto, 4099-001, Portugal
Clinical Trial Site

Bucharest, 011172, Romania
Clinical Trial Site

Cluj-Napoca, 400000, Romania
Clinical Trial Site

Belgrade, 11000, Serbia
Clinical Trial Site

Seoul, 03080, South Korea
Clinical Trial Site

Suwon, 16499, South Korea
Clinical Trial Site

Madrid, 28007, Spain
Clinical Trial Site

Kaohsiung City, 833401, Taiwan
Clinical Trial Site

Taichung, 40447, Taiwan
Clinical Trial Site

Tainan, 710, Taiwan
Clinical Trial Site

Taipei, 10002, Taiwan
Clinical Trial Site

Ankara, 06560, Turkey (Türkiye)
Clinical Trial Site

Antalya, 07070, Turkey (Türkiye)
Clinical Trial Site

Istanbul, 34096, Turkey (Türkiye)
Clinical Trial Site

Izmir, 35210, Turkey (Türkiye)
Clinical Trial Site

İzmit, 41380, Turkey (Türkiye)
Clinical Trial Site

Bath, BA1 3NG, United Kingdom
Clinical Trial Site

Manchester, M13 9PT, United Kingdom
Clinical Trial Site

Wolverhampton, WV10 0QP, United Kingdom

Conditions

Explore the condition pages connected to this study.

DERMATOMYOSITIS